BMY240830C50000
- 0.14
- +0.11+366.67%
Bristol-Myers Squibb Newsroom
Bristol-Myers Squibb Analyst Ratings
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Bristol-Myers Squibb Analyst Ratings
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Announces Target Price $42
Barclays Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY)
Jefferies Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Barclays Adjusts Bristol-Myers Squibb Price Target to $42 From $41, Maintains Underweight Rating
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating
Bristol-Myers Squibb Analyst Ratings
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $53 From $45, Maintains Hold Rating
Analysts' Top Healthcare Picks: Generation Bio (GBIO), Bristol-Myers Squibb (BMY)
Daiwa Securities Adjusts Bristol-Myers Squibb Price Target to $50 From $40
HSBC Adjusts Bristol-Myers Squibb Price Target to $50 From $45
Argus Research Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $62
Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns
Barclays Cuts Bristol Myers to Underweight, Cites Recent Run up
Wolfe Adjusts Price Target on Bristol-Myers Squibb to $57 From $55, Maintains Outperform Rating
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37